Table 1.
Characteristics of pediatric patients with or without WT1 mutations.
| All patients | WT1-mutated case | WT1 wildtype case | P-value | |
|---|---|---|---|---|
| Number (%) | 870 | 58 (6.7%) | 812(93.3%) | |
| Age, median (year) | 9.6 | 11 | 9.5 | 0.221 |
| <3years, n (%) | 211(24.3%) | 6 (10.3%) | 205 (25.2%) | 0.011 |
| 3≤Age<10years, n (%) | 237(27.2%) | 19 (32.8%) | 218 (26.8%) | 0.329 |
| 10≤Age<18years, n (%) | 422(48.5%) | 33 (56.9%) | 389 (47.9%) | 0.186 |
| Sex | 0.119 | |||
| male, n (%) | 454 (52.2%) | 36 (62.1%) | 418 (51.5%) | |
| female, n (%) | 416 (47.8%) | 22 (37.9%) | 394 (48.5%) | |
| WBC, ×109/L, | ||||
| Median (range) | 31.7(0.2-610) | 56.9(1.1-446) | 30.8(0.2-610) | 0.041 |
| FAB classification: n (%) | 0.001 | |||
| M0 | 20 (2.8%) | 1 (2.0%) | 19 (2.9%) | >0.999 |
| M1 | 96 (13.4%) | 10 (19.6%) | 86 (13.0%) | 0.181 |
| M2 | 193 (27.0%) | 11 (21.6%) | 182 (27.5%) | 0.362 |
| M3 | 2 (0.3%) | 0 (0.0%) | 2 (0.3%) | >0.999 |
| M4 | 193 (27.0%) | 21 (41.2%) | 172 (25.9%) | 0.018 |
| M5 | 160 (22.4%) | 3 (5.9%) | 157 (23.7%) | 0.003 |
| M6 | 11 (1.5%) | 4 (7.8%) | 7 (1.1%) | 0.005 |
| M7 | 39 (5.5%) | 1 (2.0%) | 38 (5.7%) | 0.351 |
| Risk group: n (%) | <0.001 | |||
| Low risk | 328 (39.0%) | 15 (27.8%) | 313 (39.8%) | 0.079 |
| Standard risk | 391 (46.5%) | 17 (31.5%) | 374 (47.6%) | 0.022 |
| High risk | 121 (14.4%) | 22 (40.7%) | 99 (12.6%) | <0.001 |
| FLT3/ITD | <0.001 | |||
| Positive, n (%) | 147 (16.9%) | 28 (48.3%) | 119 (14.7%) | |
| Negative, n (%) | 722(83.1%) | 30 (51.7%) | 692 (85.3%) | |
|
FLT3/ITD allelic ratio, Median (range) |
0.54 | 0.55 | 0.54 | 0.865 |
| (0.03-9.50) | (0.03-5.19) | (0.03-9.50) | ||
| NPM1 | 0.794 | |||
| Positive, n (%) | 66(7.6%) | 3(5.3%) | 63(7.8%) | |
| Negative, n (%) | 802(92.4%) | 63(94.7%) | 748(92.2%) | |
| CEBPA | 0.245 | |||
| Positive, n (%) | 49(5.7%) | 1(1.7%) | 48(5.9%) | |
| Negative, n (%) | 817(94.3%) | 57(98.3) | 760(94.1%) | |
| Cytogenetic status | ||||
| Normal (n, %) | 196(23.7%) | 23(44.2%) | 173(22.3%) | <0.001 |
| Abnormal (n, %) | 631 (76.4%) | 29 (55.8%) | 602 (77.7%) | 0.317 |
| inv(16)(n, %) | 106(12.8%) | 9(17.3%) | 97(12.5%) | 0.046 |
| t(8;21) (n, %) | 128(15.5%) | 3(5.8%) | 125(16.1%) | |
| HSCT in 1st CR | 0.906 | |||
| No (n, %) | 663 (83.8%) | 38 (84.4%) | 625 (83.8%) | |
| Yes (n, %) | 128 (16.2%) | 7 (15.6%) | 121 (16.2%) | |
| Protocol | 0.058 | |||
| AAML03P1 (n, %) | 91 (10.5%) | 7 (12.1%) | 84 (10.3%) | 0.679 |
| AAML0531 (n, %) | 732 (84.1%) | 44 (75.9%) | 688 (84.7%) | 0.074 |
| CCG-2961 (n, %) | 47(5.4%) | 7 (12.1%) | 40 (4.9%) | 0.031 |
| CR status at end of course 1 | 0.002 | |||
| CR, n (%) | 656 (76.3%) | 35 (60.3%) | 621 (77.4%) | 0.003 |
| Not CR, n (%) | 189 (22.0%) | 20 (34.5%) | 169 (21.1%) | 0.017 |
| Death, n (%) | 15 (1.7%) | 3 (5.2%) | 12 (1.5%) | 0.074 |
| CR status at end of course 2 | <0.001 | |||
| CR, n (%) | 736 (87.2%) | 38 (69.1%) | 698 (88.5%) | <0.001 |
| Not CR, n (%) | 88 (10.4%) | 14 (25.5%) | 74 (9.4%) | <0.001 |
| Death, n (%) | 20 (2.4%) | 3 (5.5%) | 17 (2.2%) | 0.136 |
CEBPA CCAAT, enhancer binding protein alpha; CR, complete remission; FAB, French–American–British morphology classification; FLT3/ITD, internal tandem duplication of the FLT3 gene; HSCT, hematopoietic stem cell transplantation; NPM1, Nucleophosmin; WBC, white blood cell count.